David Ricks, CEO of Eli Lilly, argues that his company has ‘one of the freshest portfolios of products’ in the pharmaceutical industry amid the acquisition of Prevail Therapeutics.
The Eli Lilly antibody product was found to significantly reduce the risk of developing symptomatic COVID-19 among residents and staff of long-term care facilities, the company said Thursday.
The drug is being evaluated as part of a Phase 3 trial with 965 participants, conducted in part by the National Institute of Allergy and Infectious Diseases and the COVID-19 Prevention Network.
Stocks in this article
The monoclonal antibody therapy, called bamlanivimab, is currently approved by the FDA for the treatment of mild to moderate COVID-19 in adult and pediatric patients 12 years of age and older who are at high risk of progressing to severe COVID. 19 and or hospitalization. The FDA said it includes patients who are 65 years or older or have certain chronic medical conditions.
ELI LILLY CEO: CORONAVIRUS TREATMENT CAN HELP ‘RELEASE’ STRESS
At the time of approval, the FDA said it had been found that the drug reduced COVID-19-related hospitalization or emergency visits to patients at high risk for disease progression within 28 days of treatment. It is not allowed for patients admitted to hospital due to COVID-19 or those who need oxygen due to the virus. No benefit was shown in patients admitted to the hospital due to the virus.
In the latest study, according to a news release posted by Eli Lilly, there was a “significantly lower frequency of symptomatic COVID-19” among the participants who received bamlanivimab compared to those who received the placebo.
AMAZON OFFERS HIDDEN HARRIS TO CONGREGATION, CLIMATE ISSUES
In a subgroup of nursing home residents, there was also a significantly lower frequency of symptomatic COVID-19 in those who received the drug versus placebo.
Four participants in the placebo group died during the trial period due to COVID-19.
The company said the results reflect an 80% lower risk of getting the virus.
“We are extremely pleased with these positive results, which have shown that bamlanivimab could help prevent COVID-19, which has significantly reduced the symptomatic disease among residents of nursing homes, some of the most vulnerable members of our society,” said Daniel Skovronsky, managing director. director, doctor. ., Lilly’s chief scientific officer and president of Lilly Research Laboratories, said in a news release.
CLICK HERE TO GET FOX BUSINESS ON THE GO
“These data provide important complementary clinical evidence regarding the use of bamlanivimab to combat COVID-19 and reinforce our belief that monoclonal antibodies such as bamlanivimab may play a critical role in reversing the tide of this pandemic.” “We are pleased that bamlanivimab is already available as a treatment for patients at high risk of progressing to severe COVID-19 disease or hospitalization, including those in nursing homes, and look forward to working with regulators to authorize expand emergency use to prevent the spread of COVID-19 in these facilities. “